AU
UK
CA
US
IND
NZ
Last update at 2025-08-21T20:04:39.731571Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
European Value Stock Picks For Estimated Discount Opportunities
Fri 23 May 25, 10:37 AMArteche Lantegi Elkartea And 2 More European Stocks That Might Be Priced Below Estimated Value
Wed 23 Apr 25, 05:37 AMThree European Undiscovered Gems With Promising Potential
Wed 23 Apr 25, 05:32 AM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 348.00M | 269.00M | 222.73M | 211.99M | 176.29M |
| Minority interest | - | - | - | - | 0.00000M |
| Net income | 268.00M | 205.00M | 175.33M | 186.82M | 167.63M |
| Selling general administrative | 529.00M | 404.00M | 375.37M | 397.75M | 323.63M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 948.00M | 755.00M | 666.73M | 685.41M | 556.63M |
| Reconciled depreciation | 102.00M | 75.00M | 73.90M | 74.37M | 39.41M |
| Ebit | 310.00M | 267.00M | 188.00M | 209.09M | 161.41M |
| Ebitda | 455.00M | 347.00M | 299.97M | 289.22M | 217.44M |
| Depreciation and amortization | - | - | - | - | - |
| Non operating income net other | - | - | - | - | 0.00000M |
| Operating income | 292.00M | 256.00M | 186.83M | 209.02M | 161.00M |
| Other operating expenses | - | 1.00M | 31.00M | -1.07700M | 4.96M |
| Interest expense | 5.00M | 3.00M | 3.34M | 2.86M | 1.74M |
| Tax provision | 80.00M | 64.00M | 47.40M | 25.17M | 8.66M |
| Interest income | 2.00M | 0.00000M | 0.35M | 0.77M | 0.63M |
| Net interest income | -3.00000M | -3.00000M | -2.99100M | -2.17200M | -1.10700M |
| Extraordinary items | - | - | - | - | 0.00000M |
| Non recurring | - | - | - | - | 0.00000M |
| Other items | - | - | - | - | 0.00000M |
| Income tax expense | 80.00M | 64.00M | 47.00M | 25.17M | 8.66M |
| Total revenue | 1566.00M | 1232.00M | 1092.28M | 1101.37M | 910.90M |
| Total operating expenses | 1274.00M | 976.00M | 905.45M | 892.36M | 749.90M |
| Cost of revenue | 618.00M | 477.00M | 425.55M | 415.96M | 354.27M |
| Total other income expense net | - | - | - | 2.98M | 15.29M |
| Discontinued operations | - | - | - | - | 0.00000M |
| Net income from continuing ops | 268.00M | 205.00M | 175.33M | 186.82M | 167.63M |
| Net income applicable to common shares | 268.00M | 205.00M | 175.00M | 186.82M | 167.63M |
| Preferred stock and other adjustments | - | - | - | - | 0.00000M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 2339.00M | 1992.00M | 1434.44M | 1335.69M | 1003.20M |
| Intangible assets | 309.00M | 313.00M | 250.79M | 260.05M | 192.65M |
| Earning assets | - | - | - | - | - |
| Other current assets | -2.00000M | 1.00M | 1.00M | -0.00100M | 0.00000M |
| Total liab | 702.00M | 620.00M | 444.40M | 460.19M | 301.02M |
| Total stockholder equity | 1637.00M | 1372.00M | 990.04M | 875.50M | 702.18M |
| Deferred long term liab | 136.00M | 128.00M | 122.00M | 105.49M | 101.21M |
| Other current liab | 335.00M | 234.00M | 145.00M | 80.25M | 6.68M |
| Common stock | 93.00M | 92.00M | 91.00M | 90.63M | 89.95M |
| Capital stock | 93.00M | 92.00M | 90.97M | 90.63M | 89.95M |
| Retained earnings | 1229.00M | 1063.00M | 956.00M | 781.12M | 692.10M |
| Other liab | 76.00M | 128.00M | 86.00M | 100.27M | 18.23M |
| Good will | 794.00M | 741.00M | 290.21M | 315.87M | 186.06M |
| Other assets | 159.00M | 154.00M | 149.00M | 151.83M | 165.26M |
| Cash | 441.00M | 311.00M | 371.32M | 185.87M | 177.02M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 417.00M | 313.00M | 217.00M | 212.27M | 173.40M |
| Current deferred revenue | - | - | - | - | - |
| Net debt | - | - | - | - | - |
| Short term debt | - | - | - | - | 0.00000M |
| Short long term debt | - | - | - | - | 0.00000M |
| Short long term debt total | - | - | - | - | - |
| Other stockholder equity | 34.00M | -49.00000M | -117.00000M | -54.21800M | -79.87700M |
| Property plant equipment | 162.00M | 128.00M | 104.00M | 112.25M | 48.63M |
| Total current assets | 1031.00M | 774.00M | 752.00M | 586.57M | 494.44M |
| Long term investments | - | - | - | 16.61M | 17.37M |
| Net tangible assets | 671.00M | 445.00M | 571.00M | 405.08M | 424.68M |
| Short term investments | - | - | - | - | 0.00000M |
| Net receivables | 285.00M | 219.00M | 212.00M | 221.62M | 180.68M |
| Long term debt | 150.00M | 150.00M | 160.80M | 178.33M | 110.60M |
| Inventory | 305.00M | 237.00M | 160.00M | 173.76M | 132.34M |
| Accounts payable | 57.00M | 56.00M | 51.00M | 41.46M | 166.72M |
| Total permanent equity | - | - | - | - | 0.00000M |
| Noncontrolling interest in consolidated entity | - | - | - | - | 0.00000M |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | 0.00000M |
| Accumulated other comprehensive income | - | - | - | - | 0.00000M |
| Additional paid in capital | - | - | - | - | 0.00000M |
| Common stock total equity | - | - | - | - | 0.00000M |
| Preferred stock total equity | - | - | - | - | 0.00000M |
| Retained earnings total equity | - | - | - | - | 0.00000M |
| Treasury stock | - | - | - | - | 0.00000M |
| Accumulated amortization | - | - | - | - | 0.00000M |
| Non currrent assets other | -1.00000M | 1.00M | 0.00300M | 0.00100M | 0.00200M |
| Deferred long term asset charges | - | - | - | - | 0.00000M |
| Non current assets total | 1308.00M | 1218.00M | 682.83M | 749.12M | 508.76M |
| Capital lease obligations | 67.00M | 53.00M | 51.89M | 59.33M | 0.00000M |
| Long term debt total | - | - | - | - | 0.00000M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -2.00000M | -2.00000M | -1.00000M | -0.68700M | -1.43700M |
| Change to liabilities | 0.00000M | 0.00000M | 0.00000M | 0.00000M | 0.00000M |
| Total cashflows from investing activities | -84.00000M | -341.00000M | -62.00000M | -85.67600M | -178.41100M |
| Net borrowings | -30.00000M | 16.00M | -23.00000M | -21.40200M | 109.94M |
| Total cash from financing activities | -133.00000M | -82.00000M | -23.00000M | -119.20500M | 19.34M |
| Change to operating activities | 51.00M | 60.00M | 23.00M | -9.26400M | 11.78M |
| Net income | 268.00M | 205.00M | 175.00M | 186.82M | 167.63M |
| Change in cash | 130.00M | -60.00000M | 185.00M | 8.85M | 2.76M |
| Begin period cash flow | 311.00M | 371.32M | 185.87M | 177.02M | 174.26M |
| End period cash flow | 441.00M | 311.00M | 371.32M | 185.87M | 177.02M |
| Total cash from operating activities | 341.00M | 353.00M | 279.00M | 211.81M | 155.00M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 102.00M | 51.00M | 52.00M | 51.05M | 21.44M |
| Other cashflows from investing activities | - | -1.00000M | -1.00000M | 0.00100M | 0.00100M |
| Dividends paid | -102.00000M | -98.00000M | -98.00000M | -97.80300M | 90.60M |
| Change to inventory | -45.00000M | -54.00000M | -5.00000M | -25.49700M | -21.41600M |
| Change to account receivables | -45.00000M | 16.00M | -9.00000M | -32.00100M | -30.02000M |
| Sale purchase of stock | - | - | - | - | 0.00000M |
| Other cashflows from financing activities | -1.00000M | -1.00000M | -1.00000M | -1.00000M | 0.00000M |
| Change to netincome | 10.00M | 51.00M | 21.00M | 18.46M | -11.72100M |
| Capital expenditures | 35.00M | 23.00M | 18.00M | 15.51M | 12.98M |
| Change receivables | - | - | - | - | 0.00000M |
| Cash flows other operating | - | - | - | - | 0.00000M |
| Exchange rate changes | - | - | - | - | 0.00000M |
| Cash and cash equivalents changes | - | - | - | - | 0.00000M |
| Change in working capital | -39.00000M | 21.00M | 9.16M | -66.76200M | -39.65500M |
| Stock based compensation | - | - | - | - | - |
| Other non cash items | -22.00000M | -1.00000M | -17.56900M | 2.13M | -11.72800M |
| Free cash flow | 271.00M | 297.00M | 218.11M | 166.35M | 107.85M |
Sector: Healthcare Industry: Medical Instruments & Supplies
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BITGF Biotage AB (publ) |
- -% | - | 49.33 | - | 0.56 | 3.38 | 6.02 | 23.92 |
| ISRG Intuitive Surgical Inc |
11.08 2.72% | 418.37 | 73.05 | 61.73 | 19.15 | 10.25 | 18.41 | 59.92 |
| ESLOF EssilorLuxottica Société anonyme |
- -% | 201.48 | 44.84 | 27.62 | 4.07 | 2.49 | 3.71 | 16.04 |
| ESLOY Essilor International SA |
4.15 4.23% | 102.32 | 41.68 | 27.25 | 3.94 | 2.45 | 3.71 | 16.04 |
| BDX Becton Dickinson and Company |
3.79 2.60% | 149.40 | 25.56 | 12.48 | 2.59 | 1.76 | 2.89 | 12.55 |
Biotage AB (publ) provides solutions and products in the areas of drug discovery and development, analytical testing, and water and environmental testing. The company offers organic and peptide synthesis solutions; flash chromotherapy, evaporation, and work-up products; flash systems; sample preparation products; plasmid purification solutions; oligo synthesis solutions; and metal scavengers and reagents, as well as accessories and spare parts. It also provides sample preparation solutions in the clinical and bioanalytical, forensic and toxicology, doping control animal and human, environment, and food and agriculture areas, as well as consumables and systems; protein purification solutions, including antibody and tagged proteins purification, automation systems, and custom packing service, as well as ion exchange, reversed phase, normal phase, and gel filtration PhyTip columns. The company sells its products to pharmaceutical and biotechnical companies, contract research and manufacturing organizations, diagnostics, clinical, environmental protection, food safety, clinical, forensic, and academic laboratories industries. It operates in more than 80 countries, which include Americas, Europe, the Middle East, Africa, and Asia Pacific. Biotage AB (publ) was founded in 1969 and is headquartered in Uppsala, Sweden.
Vimpelgatan 5, Uppsala, Sweden, 751 03
| Name | Title | Year Born |
|---|---|---|
| Mr. Tomas Blomquist | CEO & Pres | 1970 |
| Ms. Maja Nilsson | Chief Financial Officer | NA |
| Mr. Anders Wikstrom BSc, CS | Exec. VP of Operations | 1973 |
| Dr. Jon-Sverre Schanche Ph.D. | Chief Scientific Officer | 1957 |
| Mr. Lars Backman LLB | Chief Legal Officer | 1961 |
| Raffaella Bombarda | EVP of Global Marketing | 1974 |
| Ms. Petra Duprez | Chief HR & Sustainability Officer | 1965 |
| Mr. Scott Carr | Pres of Americas & Chief/Head of Americas | 1967 |
| Mr. Jonas Stahlberg | Chief Auditor | 1975 |
| Mr. Olof Nord | Exec. VP of Bus. Devel. | 1975 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...